Fiche publication
Date publication
juin 2006
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric
Tous les auteurs :
Toussirot E, Robinet E, Saas P, Chabod J, Auge B, Cozma G, Tiberghien P, Roudier J, Wendling D
Lien Pubmed
Résumé
The Escherichia Coli bacterial extract (OM-89) is used in the treatment of rheumatoid arthritis (RA). We evaluated the immunological changes induced by oral administration of OM-89 in 12 RA patients (polyclonal T cell reactivity to PHA, T cell precursor frequencies specific for OM-89 and Tetanus toxoid (TT), a control antigen and the release of Th1 (IFN-gamma, TNF-alpha), Th2 (IL-4) and T regulatory 1 cell (Tr1) (IL-10) cytokines in the supernatants of PBMC cultures. Stimulation index in response to PHA decreased at month 3 as well as T cell precursor frequencies specific for TT with similar trends for OM-89-specific T cell precursor frequencies. OM-89 induced a strong production of IL-10, a significant decrease in IL-4 production while TNF-alpha and IFN-gamma production tended to decrease during the study. Our results suggest that OM-89 has immunomodulatory properties by inducing changes in PBMC cytokines release suggestive of an induced Tr1 response to OM-89.
Référence
Autoimmunity. 2006 Jun;39(4):299-306.
